Trial reportInternational journal of chronic obstructive pulmonary disease2011
Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema.
Trial report in International journal of chronic obstructive pulmonary disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Unicentric Study Protocol of Cell Therapy in Chronic Obstructive Pulmonary Disease
Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients
Allogeneic Human Umbilical Cord-derived Mesenchymal Stem/Stromal Cells for Chronic Obstructive Pulmonary Disease (COPD): Study Protocol for a Matched Case-control, Phase I/II Trial
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis.Cells · 2022Pooled it
- Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Pooled it
- Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial.International journal of chronic obstructive pulmonary diseaseTrial
- A narrative review of stem cell-based therapy for fibrosing interstitial lung diseases: clinical evidence and translational perspectives.Frontiers in pharmacology · 2026Review
- Heterogeneous origins and functions of lung mesenchymal stromal cells.Stem cell research & therapy · 2025Article
- Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option.Stem cell research & therapy · 2024Review
- Viral airway injury promotes cell engraftment in an in vitro model of cystic fibrosis cell therapy.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Review
- Regenerative and translational medicine in COPD: hype and hope.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Article
- Genomic instability in long-term culture of human adipose-derived mesenchymal stromal cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Article
- Lung organoids: current strategies for generation and transplantation.Cell and tissue research · 2022Review
- Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022Review
- Mesenchymal stem cell treatment for enteric neuropathy in the Winnie mouse model of spontaneous chronic colitis.Cell and tissue research · 2022Article
- Repairing damaged lungs using regenerative therapy.Current opinion in pharmacology · 2021Review
- Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives.International journal of molecular sciences · 2021Review
- Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial.Stem cell research & therapy · 2021Article
- Stem cell therapy for chronic obstructive pulmonary disease.Chinese medical journal · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the chronic obstructive pulmonary disease (COPD) spectrum, lung emphysema presents, as a primarily histopathologic feature, the destruction of pulmonary parenchyma and, accordingly, an increase in the airflow obstruction distal to the terminal bronchiole. Notwithstanding the significant advances in prevention and treatment of symptoms, no effective or curative therapy has been accomplished. In this context, cellular therapy with stem cells (SCs) arises as a new therapeutic approach, with a wide application potential. The purpose of this study is to evaluate the safety of SCs infusion procedure in patients with advanced COPD (stage IV dyspnea). After selection, patients underwent clinical examination and received granulocyte colony-stimulating factor, immediately prior to the bone marrow harvest. The bone marrow mononuclear cells (BMMC) were isolated and infused into a peripheral vein. The 12-month follow-up showed a significant improvement in the quality of life, as well as a clinical stable condition, which suggest a change in the natural process of the disease. Therefore, the proposed methodology in this study for BMMC cell therapy in sufferers of advanced COPD was demonstrated to be free of significant adverse effects. Although a larger sample and a greater follow-up period are needed, it is possible to infer that BMMC cell therapy introduces an unprecedented change in the course or in the natural history of emphysema, inhibiting or slowing the progression of disease. This clinical trial was registered with ClinicalTrials.gov (NCT01110252) and was approved by the Brazilian National Committee of Ethics in Research (registration no. 14764, CONEP report 233/2009).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.